Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
Provided By GlobeNewswire
Last update: May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients
Regulatory milestone provides 10 years of market exclusivity in Europe upon approval
Read more at globenewswire.comNASDAQ:QNRX (11/7/2025, 8:10:47 PM)
9.01
+0.44 (+5.13%)
Find more stocks in the Stock Screener
